UnitedHealth Group 株価情報 (NYSE: UNH)

最新ニュース UnitedHealth Group (NYSE:UNH) 株価情報

UNITEDHEALTH GROUP INC

UnitedHealth Group

UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group Inc

EC Healthcare

United Hampshire US REIT

Health insurer stocks are trading higher after the market close on Monday following a report indicating the Trump administration will increase payment rates <a href="https://www.benzinga.com/topic/medicare">for Medicare insurers</a>.
What Happened: The Centers for Medicare and Medicaid Services (CMS) announced Monday that it will increase payment rates for Medicare insurers to 5.06%. The rate is well above the 2.23% proposed by the Biden administration and above all prior analyst expectations, according to the <a href="https://www.wsj.com/health/healthcare/private-medicare-plans-to-get-big-payment-boost-from-trump-administration-017d9aaa">Wall Street Journal</a>.
The report indicates that investors are expected to view the increase as a show of support from the Trump administration for Medicare Advantage, under which private companies can offer Medicare-approved insurance plans. 
&#8220;By finalizing these payment policies, CMS is ensuring that Medicare Advantage continues to offer access to critical services in an efficient, accountable manner, further strengthening the program's ability to serve beneficiaries,&#8221; the Medicare agency <a href="https://www.cms.gov/newsroom/press-releases/cms-finalizes-2026-payment-policy-updates-medicare-advantage-and-part-d-programs">said</a> in a press release.
The new head of CMS Mehmet Oz has long been a supporter of private insurance plans in Medicare, according to the Wall Street Journal. CMS reportedly said the payment rate increase reflects higher medical costs. 
&#8220;The actions taken by CMS help protect beneficiaries and taxpayers from waste, fraud, and abuse, while also driving access to high-quality, affordable healthcare through Medicare Advantage,&#8221; CMS said.
Here&#8217;s a look at some of the health insurer stocks making big moves following the announcement:
<ul>
<li>CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) up 6.50% at $68</li>
</ul>
<ul>
<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) up 5.77% at $555</li>
</ul>
<ul>
<li>Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) up 12.08% at $285.49</li>
</ul>
<ul>
<li>Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) up 6.35% at $450</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a></li>
</ul>
Photo: Shutterstock.

Government

News

Health Care

After-Hours Center

Movers

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Health Insurers Surge After Medicare Agency Increases Payment Rates

WIIM

ALHC

Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase payment rates for Medicare insurers.

<a href="https://www.wsj.com/health/healthcare/private-medicare-plans-to-get-big-payment-boost-from-trump-administration-017d9aaa" title="https://www.wsj.com/health/healthcare/private-medicare-plans-to-get-big-payment-boost-from-trump-administration-017d9aaa">https://www.wsj.com/health/healthcare/private-medicare-plans-to-get-big-payment-boost-from-trump-administration-017d9aaa</a>

General

WSJ: 'Medicare Advantage plans will get a 5.06% rate increase, well above the 2.23% bump that the Biden administration proposed'

Shares of the Health Care Select Sector SPDR Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NASDAQ">XLV</a>) are trading lower by 8.6% to $132.86 over the past week as tariff announcements from President Donald Trump last week spooked investors and <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">dragged major sectors</a> of the market lower. 
While healthcare is often viewed as a defensive play during times of uncertainty, the <a href="https://www.benzinga.com/general/health-care">sector</a> is not immune to the broader economic implications of escalating trade tensions.
<h2 class="wp-block-heading">What Is XLV?</h2>
The Health Care Select Sector SPDR Fund is an exchange-traded fund that tracks the performance of the Health Care Select Sector Index, which includes large U.S. healthcare companies across pharmaceuticals, biotechnology, healthcare equipment and managed care. Top holdings include Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) .
Although healthcare demand tends to be less cyclical than sectors like industrials or energy, many of XLV's components are <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">exposed to global markets</a>, supply chains and regulatory dynamics—all of which can be disrupted by a trade war.
Read Also: <a href="https://www.benzinga.com/news/25/04/44670684/whats-going-on-with-financial-select-sector-spdr-fund-xlf">What&#8217;s Going On With Financial Select Sector SPDR Fund (XLF)?</a>
<h2 class="wp-block-heading">Why Are Tariffs Hitting Healthcare—and XLV?</h2>
At first glance, healthcare might seem like an unlikely victim of tariff tensions, but the industry is more globally interconnected than it appears. Here's how tariff escalation is weighing on XLV and its underlying holdings:
<ul>
<li>Global Supply Chain Disruptions: Many medical devices and pharmaceutical ingredients are manufactured or sourced overseas. Tariffs on imported materials from countries like China can increase production costs for companies like Medtronic and Abbott Laboratories, which rely on <a href="https://www.benzinga.com/25/04/44663112/us-families-to-see-3800-annual-price-hike-says-experts-even-as-trump-indicates-tariff-windfall-of-tens-of-billions-of-dollars">international supply chains</a> to maintain margins and deliver products at scale. </li>
<li>Pricing Pressures Intensify: Healthcare companies already face intense political scrutiny over pricing. Tariffs add another <a href="https://www.benzinga.com/news/global/25/04/44668830/we-want-fairness-white-house-trade-adviser-navarro-says-trump-administration-is-focused-on-non-tariff-cheating">layer of cost inflation</a> that may be difficult to pass along to consumers or insurers. That's especially challenging for drugmakers and device manufacturers that operate under tight pricing regulations or depend on long-term contracts. </li>
<li>Global Growth Matters: Multinational pharmaceutical companies such as Pfizer and Johnson &amp; Johnson derive a significant share of their revenue from international markets. A slowdown in global economic growth due to <a href="https://www.benzinga.com/25/04/44661965/trumps-reciprocal-tariff-threat-wipes-out-nearly-18-trillion-from-magnificent-7-dan-ives-warns-it-could-set-us-tech-back-a-decade-investors-know-math-and-the-sad-reality">trade tensions</a> can dampen demand for branded drugs and medical products abroad, squeezing top-line growth. </li>
<li>Market Volatility Hits Sentiment: Even though healthcare is traditionally considered defensive, the sector is still susceptible to broader market moves. Investors often rotate out of equities—including healthcare—during times of heightened uncertainty. Additionally, biotech and life sciences stocks, many of which are included in XLV, tend to be more volatile and sensitive to shifts in investor risk appetite.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">Wall Street Turmoil Deepens As Trump Threatens Massive China Tariffs, Bitcoin Wobbles At $78K: What&#8217;s Driving Markets Monday?</a>

Why Health Care Select Sector SPDR Fund (XLV) Is Moving

Analyst Ratings

Trading Ideas

Live On CNBC, Jim Lebenthal Announces Sold UnitedHealth Group

For many investors, dividend-focused <a href="https://in.benzinga.com/25/03/44565770/30-year-old-with-65k-in-stocks-sparks-debate-focusing-mostly-on-etfs-but-now-betting-on-bonds-small-caps-and-international-plays">stocks</a> and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day <a href="https://in.benzinga.com/personal-finance/25/02/43768530/should-married-couples-split-expenses-dave-ramsey-says-no-youre-married-not-roommates">expenses</a>, or even finance small luxuries like annual vacations.
While some aim for significant <a href="https://in.benzinga.com/personal-finance/25/03/44518501/20-year-old-university-student-wants-help-with-buying-dividend-stocks-whats-the-best-way-to-start-reddit-weights-in">dividend</a> payouts to replace their salary, others are happy with modest but constant returns that offer a little extra financial freedom.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
This is the case of a Reddit user who is exploring this approach. With $30,000 to invest, he's seeking long-term dividend stocks that can grow over the next 20 years until retirement. While he already holds dividend-paying stocks like Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Walt Disney&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), he wants to expand his portfolio for stability and future income, even if it's just enough to cover yearly vacations.
&#8220;I currently have some stocks that give out dividends (Apple, Disney) but I&#8217;m looking for others. Long-term stability, that my wife and I can use the dividends as another form of income say in 20 years. Even if it&#8217;s just enough to pay for a yearly vacation here or there. Any thoughts on good companies to choose from?&#8221; he asked.
Let&#8217;s break down the Redditors&#8217; advice received in the comment section.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Where to Invest $30,000 to Generate Enough Income to Cover Yearly Vacations? Reddit Answers</h2>
Put the Money in an ETF
Several commenters recommended Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) as a core holding because of its dividend yield, historical growth, and the low-risk, diversified exposure it offers investors.
&#8220;Go all in SCHD. Low risk, nice 3.5% starting yield and it will just keep growing,&#8221; a commenter said.
Reinforcing the idea that SCHD fits the poster&#8217;s long-term stability and dividend payout need, this Redditor also suggested he goes with SCHD: &#8220;Since you want some growth and decent payout, SCHD is a great option. 3.5% dividends and 11% growth over the last 10 years each year.&#8221;
&#8220;I would stick with S&amp;P 500 ETFs being young. Put it in a self-direct investment retirement account to avoid taxes,&#8221; a comment reads.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Consider High-Yield Dividend Stocks and Trusts
Several commenters suggested higher-yield assets that would generate higher payouts for the investor in the long run.
&#8220;If you want higher yield stocks check: [Verizon Communications (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vz#NYSE">VZ</a>)], [AT&amp;T (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>)], [Realty Income Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/o#NYSE">O</a>)], [Altria Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mo#NYSE">MO</a>)], [British American Tobacco (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bti#NYSE">BTI</a>)],&#8221; a Redditor recommended.
A commenter mentioned United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) as a great pick since the company seems to start focusing on higher profit margin areas.
&#8220;UPS pays a solid dividend and the share price has been beaten down a lot on the news that they are reducing Amazon deliveries to focus on higher profit margin areas,&#8221; he said.
Suggesting a very detailed portfolio allocation, this Redditor mentioned several ETFs and individual stocks that he considers would help the poster reach his dividend and growth goals.
&#8220;[Vanguard S&amp;P 500 ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/voo#NYSE">VOO</a>)] $5,000, 1.25% dividends. Do [dividend reinvestment plan] SCHD $5,000, 3.5% dividends. Do [dividend reinvestment plan], [JPMorgan Equity Premium Income ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jepi#NYSE">JEPI</a>)], [JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jepq#NASDAQ">JEPQ</a>)​] ($5,000), 8% combined dividends. Do [dividend reinvestment plan] [Old Republic International Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ori#NYSE">ORI</a>)] $2,000, 3% dividends. Do [dividend reinvestment plan] [Waste Management (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wm#NYSE">WM</a>)] and [Automatic Data Processing (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adp#NASDAQ">ADP</a>)] ($3,000), 2% average dividend. Do [dividend reinvestment plan] [Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>)] and [Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>)] $2,000, 4.75% average dividend. Do [dividend reinvestment plan] [JPMorgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>)] and [UnitedHealth Group Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>)] $2,000, 2% average dividends. Do [dividend reinvestment plan] AAPL and [Microsoft (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>)] $2,000. [The Coca-Cola Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>)] and MO $2,000, 5% average dividends. Do [dividend reinvestment plan] JPM or [American Express (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axp#NYSE">AXP</a>)] $2,000. JPM has good potential growth,&#8221; the suggestion says.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

AAPL

JEPI

JEPQ

MSFT

SCHD

Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts

In September, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark, Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">price of insulin medications</a>.
The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.
The FTC is now pausing after the agency submitted <a href="https://www.ftc.gov/system/files/ftc_gov/pdf/d9437_2025.04.01_commorderstayingadjudication.pdf" target="_blank" rel="noreferrer noopener">an order</a> seeking an administrative stay in the case.
Also Read:<a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43010888/ftc-says-unitedhealth-cvs-cigna-make-billions-via-pbms-on-specialty-drugs" rel="noreferrer noopener"> FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs</a>
The agency does not cite any sitting commissioners who can join the proceedings. The two sitting commissioners, Republicans Andrew Ferguson and Melissa Holyoak, <a href="https://www.benzinga.com/government/24/10/41172976/texas-attorney-general-sues-insulin-manufacturers-and-pharmacy-benefit-managers-over-price-fixing-co" target="_blank" rel="noreferrer noopener">have recused themselves</a>.
According to the order filed this week, the stay will remain in place for at least 105 days. The courts also set an evidentiary hearing for 225 days after the stay lifts.
Reuters notes that of its five sitting commissioners, two were fired, two were removed from the case, and one resigned when Trump took office.
Several state and local governments also filed lawsuits against drug companies and pharmacy benefit managers, accusing them <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40560002/governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-r" rel="noreferrer noopener">of inflating insulin prices</a>.
In November 2024, the FTC faced legal challenges from three competing pharmacy-benefit managers over its attempt to restrict their ability to negotiate drug prices for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system" rel="noreferrer noopener">health plan sponsors</a>.
The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.
The companies also&nbsp;contend&nbsp;that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.
Price Action: CI stock is down 1.13% at $328.16, UNH stock is up 0.04% at $523.40, and CVS stock is down 0.85% at $67.49&nbsp;during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44614073/sportradars-big-bet-on-sports-data-analyst-raises-2026-forecast-sees-major-growth-in-live-betting" target="_blank" rel="noreferrer noopener">Sportradar&#8217;s Bets Big On Sports Data, Analyst Says Company Has Favorable Setup</a></li>
</ul>
Image: Shutterstock

Large Cap

Legal

FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth's PBMs Amid Commissioner Shortage

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/03/28/final-trades-paypal-meta-abbvie-and-snowflake.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said Kinsale Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) continues to move toward record high levels and the <a href="https://www.benzinga.com/quote/KNSL/analyst-ratings">stock looks &#8220;great.&#8221;</a>
Supporting his view, Truist Securities analyst Mark Hughes, on Feb. 18, maintained Kinsale Cap Group with a Buy rating and raised the price target from $480 to $525.
Jim Lebenthal of Cerity Partners picked PG&amp;E Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>), a North California utility.
On the earnings front, PG&amp;E will hold a conference call on Thursday, April 24, to discuss its first quarter 2025 results. Analysts expect the company to report quarterly earnings at 40 cents per share, up from 37 cents per share in the year-ago period. PG&amp;E projects quarterly revenue of $6.23 billion, compared to $5.86 billion a year earlier.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Stephanie Link of Hightower Advisors named UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) as her final trade.
UnitedHealth Group will release its first quarter financial results before the opening bell on Thursday, April 17. Analysts expect the healthcare company to report quarterly earnings at $7.31 per share, up from $6.91 per share in the year-ago period. UnitedHealth projects quarterly revenue of $111.6 billion, compared to $99.8 billion a year earlier.
Price Action:
<ul>
<li>Kinsale Capital gained 0.3% to close at $488.15 on Tuesday.</li>
<li>PG&amp;E Corporation shares rose 0.5% to close at $17.27 during Tuesday's session.</li>
<li>UnitedHealth Group shares slipped 0.1% to settle at $523.12 on Tuesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44584246/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Markets

Media

KNSL

UnitedHealth Group, PG&E And A Financial Stock On CNBC's 'Final Trades'

Attorney General Pam Bondi <a href="https://www.justice.gov/opa/pr/attorney-general-pamela-bondi-directs-prosecutors-seek-death-penalty-luigi-mangione">announced</a> today that federal prosecutors will seek the death penalty against Luigi Mangione, the 26-year-old accused of murdering a UnitedHealthcare Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) executive in what authorities call a <a href="https://www.justice.gov/opa/pr/attorney-general-pamela-bondi-directs-prosecutors-seek-death-penalty-luigi-mangione">politically motivated assassination</a>.
What To Know: Bondi described the Dec. 4, 2024, killing of Brian Thompson as a "premeditated, cold-blooded assassination" and reaffirmed her commitment to <a href="https://www.justice.gov/ag/media/1388561/dl?inline=&amp;utm_medium=email&amp;utm_source=govdelivery">restoring</a> the federal death penalty. 
"Mangione's actions shocked America," Bondi stated, emphasizing that the move aligns with President Trump's agenda to combat violent crime.
Mangione, who grew up in a wealthy Baltimore real estate family, allegedly targeted Thompson as part of a broader statement against the healthcare industry. Authorities <a href="https://www.benzinga.com/markets/24/12/42512814/luigi-mangione-lived-a-privileged-life-of-real-estate-wealth-before-arrest-in-ceo-case">found a manifesto</a> detailing his grievances, along with a 3D-printed gun and silencer at the time of his arrest.
Federal charges against Mangione were filed on Dec. 19. Bondi has now instructed Acting U.S. Attorney Matthew Podolsky to pursue the death penalty.
The case has meanwhile sparked public debate, with some supporters criticizing the healthcare sector and <a href="https://in.benzinga.com/news/legal/25/02/43887520/luigi-mangione-back-in-court-friday-supporters-donate-500k-to-suspected-killer">donating over $514,000</a> to Mangione's legal defense fund.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44591525/wall-street-inches-up-ahead-of-tariff-day-whats-driving-markets-tuesday">Wall Street Inches Up Ahead Of Tariff Day: What&#8217;s Driving Markets Tuesday?</a>
What Else: The US Attorney General&#8217;s office on Feb. 5 announced the <a href="https://www.justice.gov/ag/media/1388561/dl?inline=&amp;utm_medium=email&amp;utm_source=govdelivery">revival</a> of the federal death penalty, immediately lifting the moratorium on federal executions.
According to the memo, federal prosecutors are now directed to actively seek the death penalty in cases involving offenses such as the murder of law enforcement officers and capital crimes committed by undocumented individuals. &nbsp;
This policy shift also includes a review of past decisions where the death penalty was not pursued, indicating a firm stance on capital punishment. The federal government will also assist states in implementing death sentences.
As Mangione's trial continues, Bondi's strong support for capital punishment will likely remain a key focus, highlighting the administration's tough-on-crime policies.
Read Also
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44584000/veteran-investor-warns-of-rising-stagflation-risk-as-tariffs-loom-anticipates-squeezed-profit-margins-for-us-businesses">Veteran Investor Warns Of Rising Stagflation Risk As Tariffs Loom, Anticipates &#8216;Squeezed Profit Margins&#8217; For US Businesses</a></li>
</ul>

Politics

AG Pam Bondi Seeks Death Penalty For UnitedHealthcare Exec's Murder

UnitedHealth Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) short percent of float has risen 17.89% since its last report. The company recently reported that it has 10.25 million shares sold short, which is 1.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>UnitedHealth Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743527727_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UnitedHealth Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing UnitedHealth Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, UnitedHealth Group's peer group average for short interest as a percentage of float is 5.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into UnitedHealth Group's Recent Short Interest

CNBC Halftime Report Final Trades: UnitedHealth Group, Kinsale Capital, Pacific Gas & Electric

Knowing which <a href="https://www.benzinga.com/personal-finance/25/03/44376666/high-yield-dividend-investor-making-12900-per-year-names-10-favorite-stocks-took-me-almost-3-years-to-get-to-this-point">stocks</a> to hold for the long term and which to sell before they drag down your portfolio is a challenge every investor faces at least once in their journey.
Some swear by the &#8220;buy and hold&#8221; strategy, while others advocate for constant rebalancing of a portfolio to mitigate <a href="https://www.benzinga.com/personal-finance/25/03/44476778/author-says-dave-ramsey-is-completely-ignorant-of-sequence-of-returns-risk-questions-whether-1-million-is-really-enough-for-retirement">risk</a>. The issue becomes even more pronounced when a portfolio is heavily condensed in high-growth but volatile sectors like technology.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
One such investor recently took to Reddit to seek advice on his $14,228 portfolio, which includes tech giants like Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)​, Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>, GOOG)), and Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), alongside ETFs like Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) and Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), and even some crypto-linked stocks like Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>).
The poster is considering adding Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) to his portfolio but is unsure if now is the right time. He&#8217;s also wondering whether to keep high-risk stocks like TSLA, COIN, and MSTR or shift to more stable assets and how to diversify his portfolio further.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
The Reddit community has come forward with plenty of advice in the comments; let&#8217;s see what they say.
<h2 class="wp-block-heading">Hold or Sell? Investor With $14,000 Tech-Heavy Portfolio Ponders Diversification–Reddit Advises Him</h2>
Diversify into Other Sectors or Broader ETFs
Many Redditors indicated that the investor&#8217;s portfolio is way too concentrated in tech, which increases risk. Instead, they suggested reducing individual stock holdings and adding ETFs to gain exposure to other sectors.
&#8220;I am sure you know this, but VOO/QQQ includes all of the individual companies that you have the majority of your portfolio invested in,&#8221; a comment says.
Advising the poster to diversify his portfolio, one Redditor suggested choosing either VOO or QQQ, but not both.
&#8220;You own good companies! Personally, I would choose one of the two VOO/QQQ not both, but that&#8217;s just me and is not really a big deal&#8230; Other than that, I like everything else; I think I own all of them, except COIN. Look into buying other sectors, you are too heavily concentrated on tech.&#8221;
A commenter advised the poster to add a broad-market ETF to reduce complexity and risk.
&#8220;Too complex for this volume, many duplicates and missing diversification. Just do VOO or an [MSCI (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/msci#NYSE">MSCI</a>)] world index and that's it,&#8221; he wrote.
&#8220;VOO and QQQ are redundant and lend even more weight to the Mag 7. COIN, MSTR, TSLA, and NVDA are no-go long-term, I think. Try to add something more stable like [Raytheon Technologies (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rtx#NYSE">RTX</a>)], [UnitedHealth Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>)], or [The Coca-Cola Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>)],&#8221; a user suggested.
A Redditor recommended the investor add a mix of ETFs and stable dividend-paying stocks to improve the portfolio&#8217;s resilience.
&#8220;Continue with VOO, [Invesco NASDAQ 100 ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqqm#NASDAQ">QQQM</a>)] only, and get some solid plays added from now on, diversify a bit. Can stick with ETFs or index, defense, utilities, energy, health care, precious metals, [Berkshire Hathaway (NYSE: BRK.A, BRK.B)], with the trade war, you need stuff that can survive. Look for some balance now with solid legacy names with dividends,&#8221; he wrote.
See Also: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Sell TSLA, COIN, and MSTR
The poster&#8217;s most controversial holdings were TSLA, COIN, and MSTR, and some commenters argued that he should get rid of them since they&#8217;re too risky for a 10-year hold.
&#8220;Sell the TSLA and take the win; it's overvalued dramatically,&#8221; a comment reads.
&#8220;I'd scrub TSLA and MSTR and put it in VOO or QQQ. Tesla's valuation is and has been insane forever, even after the sell-off. The fundamentals are just awful for its valuation. And that's not even dipping into political stuff. Plus, it's already a decent weight in VOO anyway. And MSTR is straight-up junk,&#8221; a Redditor said.
This user also suggested selling the three stocks, saying, &#8220;I would personally remove MSTR, COIN, and TSLA and buy more of QQQ/VOO.&#8221;
&#8220;Get rid of TSLA before it wrecks your portfolio!&#8221; another comment reads.
One Redditor shared he would never hold MSTR for the long term, and suggested HOOD instead of COIN.
&#8220;No way I would hold MSTR for 10 years. You are playing crypto with COIN; in my opinion, HOOD is the better bet now that they are getting into the higher-margin gambling business. If you want Bitcoin exposure, buy [iShares Bitcoin Trust (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibit#NASDAQ">IBIT</a>)].
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/arrived-centennial">Jeff Bezos-Backed Arrived Homes Hits A Big Sale On Charlotte Property – Investors Earning A 34.7% Return</a></li>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>

AMZN

COIN

GOOGL

HOOD

IBIT

MSCI

MSTR

NVDA

QQQM

TSLA

$14K Investor In TSLA, NVDA, And QQQ Faces Dilemma – 'Looking To Hold For At Least 10 Years' But Is That A Recipe For Disaster? Reddit Debates

If you&#8217;re analyzing contrarian opportunities in 2025, this list is worth studying. It highlights names that, despite widespread skepticism, have been <a href="https://www.benzinga.com/analyst-stock-ratings">outperforming more popular picks.</a>
In a year when Wall Street&#8217;s darlings have stumbled, some of the most unloved names in the S&amp;P 500 are quietly delivering gains that put high-conviction buys to shame—and the data may challenge how investors think about analyst ratings.
In a newsletter sent Tuesday, DataTrek Research spotlighted what it called "a truly remarkable list": the 10 S&amp;P 500 companies with the highest share of &#8216;Sell&#8217; ratings from analysts. 
&#8220;History and year-to-date returns suggest it is a good place to look for longs,&#8221; analysts suggested.
<h3 class="wp-block-heading">The Contrarian Play: Most-Hated, Yet Outperforming</h3>
&#8220;Wall Street analysts don&#8217;t put &#8216;Sell&#8217; on many stocks,&#8221; Datatrek wrote.
FactSet data shows that of the 12,320 ratings issued on S&amp;P 500 stocks, 55.7% are Buys, 38.7% are Holds, and only 5.6% are Sells.
&#8220;The percentage of Buy ratings is above its 5-year (month-end) average of 55.0%. The percentage Hold ratings is below its 5-year (month-end) average of 39.1%. The percentage of Sell ratings is also below its 5-year (month-end) average of 5.9%,&#8221; FactSet said.
Here are the 10 S&amp;P 500 stocks with the highest percentage of Sell ratings:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Buy</td>
<td>Hold</td>
<td>Sell</td>
</tr>
<tr>
<td>Franklin Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>)</td>
<td>0%</td>
<td>60%</td>
<td>40%</td>
</tr>
<tr>
<td>VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>)</td>
<td>40%</td>
<td>20%</td>
<td>40%</td>
</tr>
<tr>
<td>Expeditors Intl. of Washington, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>)</td>
<td>0%</td>
<td>61%</td>
<td>39%</td>
</tr>
<tr>
<td>T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>)</td>
<td>6%</td>
<td>59%</td>
<td>35%</td>
</tr>
<tr>
<td>Paramount Global Class B (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)</td>
<td>13%</td>
<td>52%</td>
<td>35%</td>
</tr>
<tr>
<td>FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>)</td>
<td>17%</td>
<td>50%</td>
<td>33%</td>
</tr>
<tr>
<td>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>)</td>
<td>24%</td>
<td>43%</td>
<td>33%</td>
</tr>
<tr>
<td>Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>)</td>
<td>10%</td>
<td>60%</td>
<td>30%</td>
</tr>
<tr>
<td>Consolidated Edison, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>)</td>
<td>6%</td>
<td>65%</td>
<td>29%</td>
</tr>
<tr>
<td>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</td>
<td>20%</td>
<td>52%</td>
<td>28%</td>
</tr>
</tbody>
</table>
</figure>
As counterintuitive as it may seem, an equal-weighted portfolio of these &#8220;Sell-rated&#8221; stocks would have returned 3.89% year-to-date through March 25, 2025.
Here&#8217;s how the individual &#8220;Sell&#8221; stocks performed:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Total Return (YTD)</td>
</tr>
<tr>
<td>Consolidated Edison, Inc.</td>
<td>19.35%</td>
</tr>
<tr>
<td>VeriSign, Inc.</td>
<td>18.78%</td>
</tr>
<tr>
<td>Paramount Global</td>
<td>11.45%</td>
</tr>
<tr>
<td>Expeditors International of Washington, Inc.</td>
<td>6.88%</td>
</tr>
<tr>
<td>Garmin Ltd.</td>
<td>6.33%</td>
</tr>
<tr>
<td>Southwest Airlines Co.</td>
<td>3.72%</td>
</tr>
<tr>
<td>Franklin Resources, Inc.</td>
<td>-1.33%</td>
</tr>
<tr>
<td>Lennox International Inc.</td>
<td>-3.62%</td>
</tr>
<tr>
<td>FactSet Research Systems Inc.</td>
<td>-8.25%</td>
</tr>
<tr>
<td>T. Rowe Price Group, Inc.</td>
<td>-14.42%</td>
</tr>
</tbody>
<tfoot>
<tr>
<td>Average</td>
<td>3.89%</td>
</tr>
</tfoot>
</table>
</figure>
That performance handily beats the -2.36% decline of the S&amp;P 500, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), and it's miles ahead of the -10% drop in the Magnificent Seven cohort, tracked by the Roundhill Magnificent Seven ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NYSE">MAGS</a>).
<h3 class="wp-block-heading">The "Buy" Darlings Didn't Deliver</h3>
Now, contrast that with the 10 most-loved stocks in the S&amp;P 500 — the ones with the highest percentage of Buy ratings.
This basket includes mega-cap giants like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), all ranked in the top tier for analyst sentiment.
But the returns tell a different story. An equal-weighted portfolio of these "Buy-rated" favorites would have lost 4.44% so far in 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Buy</th>
<th>Hold</th>
<th>Sell</th>
<th>YTD Return</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>97%</td>
<td>0%</td>
<td>3%</td>
<td>+1.97%</td>
</tr>
<tr>
<td>Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>)</td>
<td>96%</td>
<td>0%</td>
<td>4%</td>
<td>-19.34%</td>
</tr>
<tr>
<td>VICI Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>)</td>
<td>96%</td>
<td>4%</td>
<td>0%</td>
<td>+9.77%</td>
</tr>
<tr>
<td>Microsoft Corp. </td>
<td>95%</td>
<td>5%</td>
<td>0%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Amazon.com Inc.</td>
<td>95%</td>
<td>5%</td>
<td>0%</td>
<td>-6.22%</td>
</tr>
<tr>
<td>Nvidia Corp.</td>
<td>93%</td>
<td>7%</td>
<td>0%</td>
<td>-10.14%</td>
</tr>
<tr>
<td>United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</td>
<td>92%</td>
<td>4%</td>
<td>4%</td>
<td>-18.75%</td>
</tr>
<tr>
<td>Trimble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>)</td>
<td>92%</td>
<td>8%</td>
<td>0%</td>
<td>-0.27%</td>
</tr>
<tr>
<td>Synopsys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>)</td>
<td>91%</td>
<td>9%</td>
<td>0%</td>
<td>-5.79%</td>
</tr>
<tr>
<td>Teledyne Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>)</td>
<td>91%</td>
<td>9%</td>
<td>0%</td>
<td>+10.41%</td>
</tr>
<tr>
<td>Average</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>-4.44%</td>
</tr>
</tbody>
</table>
</figure>
Bottom line, the trend offers a striking insight: being unloved by analysts doesn't necessarily doom a stock to underperformance. 
In fact, in a year marked by pullbacks in big tech and sector rotations, contrarian plays are quietly thriving.
For those willing to swim against the tide, Wall Street's least-favored stocks may hold the key to outperformance this year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44473410/trumps-tariff-rates-could-be-double-what-market-participants-expect-goldman-sachs-warns">Trump&#8217;s Tariff Rates Could Be &#8216;Double What Market Participants Expect,&#8217; Goldman Sachs Warns</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Equities

Sector ETFs

Tech

ETFs

EXPD

GRMN

MAGS

PARA

SNPS

TRMB

TROW

VICI

VRSN

Want To Buy Stocks In 2025? There's One Conflicting Place To Find Winners, Analyst Says

Bloomberg: 'A Senate panel backed Mehmet Oz to lead the Centers for Medicare and Medicaid Services, sending his nomination to the full chamber for a final vote.'

On CNBC's &#8220;Halftime Report Final Trades,&#8221; Joshua Brown of Ritholtz Wealth Management named Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) <a href="https://www.benzinga.com/markets/25/02/43685595/chevron-announces-about-20-workforce-reduction-in-cost-saving-initiative-responsible-leadership-requires-taking-these-steps">his final trade</a>.
On Feb. 12, Chevron announced plans to slash its workforce by up to 20% and intends to commence major layoffs this year, aiming to complete the majority by the end of 2026. The move is part of a broader cost-cutting plan, with the company targeting a reduction of $2 billion to $3 billion by the end of 2026, reported CNBC
Jason Snipe of Odyssey Capital Advisors said he likes Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>). On March 19, Fiserv announced that it had acquired CCV, a payment solutions provider in the Netherlands, Belgium and Germany, to drive growth in the European market.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners picked UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) as his final trade.
On Thursday, UnitedHealth Group's Optum Rx will align payment models more closely to the costs pharmacies may face due to manufacturer pricing actions. The company plans a full implementation by January 2028.
Price Action:
<ul>
<li>Chevron shares gained 0.4% to close at $164.77 on Thursday.</li>
<li>Fiserv rose 0.7% to settle at $221.79 during Thursday's session.</li>
<li>UnitedHealth Group shares gained 1.6% to close at $511.30 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>
Photo: Courtesy: zignal_88 on Shutterstock.com

Chevron, Fiserv And A Health Care Stock On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Chevron, Fiserv, UnitedHealth Group

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 5.16% on an annualized basis producing an average annual return of 15.88%. Currently, UnitedHealth Group has a market capitalization of $465.40 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 10 years ago, it would be worth $4,307.40 today based on a price of $508.79 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

On Thursday, UnitedHealth Group Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum Rx will align payment models more closely to the costs pharmacies may face due to <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">manufacturer pricing actions</a>.
The company plans a full implementation by January 2028.
In February, President&nbsp;Donald Trump&nbsp;signed an executive order to strengthen price transparency regulations&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43988275/healthcare-stocks-decline-after-trump-signs-executive-order-on-price-transparency" rel="noreferrer noopener">in the industry.</a>
The order directs federal agencies, including the Departments of Treasury, Labor, and Health and Human Services, to enforce and expand a 2019 rule requiring hospitals and insurers to publicly disclose the actual costs of medical services.
This change will positively impact Optum Rx&#8217;s non-affiliated network pharmacies, including the more than 24,000 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44413134/optum-rx-to-modernize-pharmacy-payment-models" rel="noreferrer noopener">independent community pharmacies</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44198209/vertex-newly-approved-pain-treatment-lands-higher-cost-tier-3-placement-in-unitedhealths-optum-rx-formularies" rel="noreferrer noopener">Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth&#8217;s Optum Rx Formularies</a>
&#8220;Pharmacies and pharmacists provide important care to patients, and we recognize that increasing drug prices make it hard for them to afford needed medicines, especially independent and community pharmacies,&#8221; said Patrick Conway, CEO of Optum Rx. &#8220;This move will help correct imbalances in how pharmacies are paid for brand and generic drugs and will ensure greater access to medicines for patients across the country.&#8221;
Optum Rx will similarly transition client arrangements—such as employer and health plan customers—to ensure transparency and greater alignment with drug costs.
Optum Rx has been working to ensure pharmacies are paid fairly and offering solutions to improve operational efficiency and reduce administrative burden. Some of these efforts include:
<ul>
<li>Reimbursing pharmacists for connecting their underserved patients to services that address basic needs such as food, nutrition, transportation, housing, and baby supplies. Key areas of focus include maternal wellness and meeting health care needs in urban and rural communities with few pharmacies.</li>
<li>Supporting independent pharmacists by paying them for services such as counseling and medication management.</li>
<li>Enhancing pharmacy digital capabilities to easily access claims and payment data, ease administrative burdens, and manage revenue.</li>
<li>Removing retroactive recoupment (clawbacks) for pharmacies.</li>
<li>Offering predictive analytics and other tools.</li>
</ul>
On Wednesday, Optum Rx announced that it would eliminate up to 25% of reauthorizations, equal to more than 10% of overall pharmacy prior authorizations, to&nbsp;make prescription drugs more affordable and the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44394094/optum-rx-further-simplifies-consumer-access-to-prescription-drugs" rel="noreferrer noopener">pharmacy experience simpler</a>.
The initiative focuses first on approximately 80 drugs, and Optum Rx will work with physicians and pharmacists to expand the list over time.
Optum Rx said that some reauthorizations are necessary for drugs with safety concerns, which need ongoing monitoring for dose adjustments, require additional tests, or may have alternative therapy considerations.
For example, new drugs developed for Alzheimer&#8217;s disease carry risks for the brain, and long-term effectiveness is not clear.
For these treatments, ongoing review is important for patients, payers and physicians. In contrast, once a genetic condition like cystic fibrosis is confirmed through testing, there is minimal additional value in reauthorizing an effective, lifelong treatment.
Price Action: UNH stock is up 0.36% at $505 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44415152/microsoft-to-launch-malaysias-first-cloud-region-with-three-data-centers" target="_blank" rel="noreferrer noopener">Microsoft To Launch Malaysia&#8217;s First Cloud Region With Three Data Centers</a></li>
</ul>
Image: Shutterstock

UnitedHealth To Overhaul Payment Model To Support Independent Pharmacies

UnitedHealth's Optum Rx Plans To Align Payment Models More Closely To The Costs Pharmacies May Face Due To Manufacturer Pricing Actions

UnitedHealth's Optum Rx Says It Is Eliminating Up To 25% Of Reauthorizations, Which Is Equal To More Than 10% Of Overall Pharmacy Prior Authorizations, The Initiative Focuses First On Approximately 80 Drugs, And Optum Rx Will Work With Physicians And Pharmacists To Expand The List Over Time

Press Releases

AM Best Affirms Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of UnitedHealth Group Incorporated - UNH

UnitedHealth Group Announcement: UNH Investors Are Encouraged to Contact The Rosen Law Firm About Ongoing Investigation of Breaches of Fiduciary Duties by the Directors and Officers – UNH

Optum Rx Further Simplifies Consumer Access to Prescription Drugs

Optum Rx to Modernize Pharmacy Payment Models

UnitedHealth Group Announces Earnings Release Date

UNH Announcement: UnitedHealth Group Investors Are Encouraged to Contact The Rosen Law Firm About Ongoing Investigation of Breaches of Fiduciary Duties by the Directors and Officers – UNH

Comments

UnitedHealth Group

ニュース

最新ニュース UnitedHealth Group (NYSE:UNH) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル